Article

Gemtuzumab Ozogamicin

Kathy Wilkinson

Carol Viele

acute leukemia
CJON 2002, 6(5), 298-304. DOI: 10.1188/02.CJON.298-299

Gemtuzumab ozogamicin is indicated for the treatment of CD33 positive acute myeloid leukemia (AML) in patients 60 years of age or older in first relapse who are not candidates for cytotoxic chemotherapy. The CD33 antigen is expressed on more than 80% of patients with AML.

Members Only
Not a current ONS member or journal subscriber?

Become a Member

Explore the benefits of membership.
Join ONS or Renew Membership

Purchase This Article

Receive a PDF to download and print.